Terns Pharmaceuticals Stock Performance

TERN Stock  USD 37.77  2.43  6.88%   
Terns Pharmaceuticals holds a performance score of 14 on a scale of zero to a hundred. The entity has a beta of -0.5, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Terns Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Terns Pharmaceuticals is likely to outperform the market. Use Terns Pharmaceuticals potential upside, as well as the relationship between the kurtosis and day typical price , to analyze future returns on Terns Pharmaceuticals.

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Terns Pharmaceuticals are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Terns Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more

Actual Historical Performance (%)

One Day Return
6.76
Five Day Return
8.54
Year To Date Return
(5.93)
Ten Year Return
105.17
All Time Return
105.17
Last Split Factor
1000:50
Last Split Date
2013-11-04
1
Tern Trading 15.9 percent Higher Heres Why
11/12/2025
2
Terns Pharmaceuticals Hits New 52-Week High Heres What Happened
11/26/2025
3
Terns Pharmaceuticals Valuation Check After Strong CARDINAL Trial Data for CML Candidate TERN-701
12/16/2025
4
Tern Pharmaceuticals Soars 630 percent on CML Treatment Best-in-Class Potential
01/02/2026
5
Disposition of 150000 shares by Burroughs Amy L. of Terns Pharmaceuticals subject to Rule 16b-3
01/05/2026
6
Disposition of 200 shares by Kuriakose Emil of Terns Pharmaceuticals at .6 subject to Rule 16b-3
01/06/2026
7
Assessing Terns Pharmaceuticals Valuation After Recent Share Price Swings And Elevated Price To Book Ratio
01/09/2026
8
TERN-701s Superior Efficacy and Safety in CML Underpin Buy Rating and Top 2026 Pick on Terns Pharmaceuticals - TipRanks
01/13/2026
9
Wall Street Forecasts 42.31 percent Upside To Terns Pharmaceuticals, Inc.
01/15/2026
10
Acquisition by Andrew Gengos of 137500 shares of Terns Pharmaceuticals at 37.18 subject to Rule 16b-3
01/16/2026
11
Acquisition by Fellows David A of 2828 shares of Terns Pharmaceuticals at 34.6 subject to Rule 16b-3
01/30/2026
12
What Terns Pharmaceuticals s Expanded Global Rights to TERN-701 Mean For Shareholders
02/02/2026
13
Tern Trading Up 15.6 percent Time to Buy
02/05/2026
Begin Period Cash Flow79.9 M
Total Cashflows From Investing Activities-12.4 M

Terns Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  2,058  in Terns Pharmaceuticals on November 11, 2025 and sell it today you would earn a total of  1,719  from holding Terns Pharmaceuticals or generate 83.53% return on investment over 90 days. Terns Pharmaceuticals is currently generating 1.1744% in daily expected returns and assumes 6.3182% risk (volatility on return distribution) over the 90 days horizon. In different words, 56% of stocks are less volatile than Terns, and 77% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Terns Pharmaceuticals is expected to generate 7.83 times more return on investment than the market. However, the company is 7.83 times more volatile than its market benchmark. It trades about 0.19 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.09 per unit of risk.

Terns Pharmaceuticals Target Price Odds to finish over Current Price

The tendency of Terns Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 37.77 90 days 37.77 
about 29.4
Based on a normal probability distribution, the odds of Terns Pharmaceuticals to move above the current price in 90 days from now is about 29.4 (This Terns Pharmaceuticals probability density function shows the probability of Terns Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Terns Pharmaceuticals has a beta of -0.5. This usually implies as returns on the benchmark increase, returns on holding Terns Pharmaceuticals are expected to decrease at a much lower rate. During a bear market, however, Terns Pharmaceuticals is likely to outperform the market. Moreover Terns Pharmaceuticals has an alpha of 1.741, implying that it can generate a 1.74 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Terns Pharmaceuticals Price Density   
       Price  

Predictive Modules for Terns Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Terns Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
29.5935.9142.23
Details
Intrinsic
Valuation
LowRealHigh
37.5543.8750.19
Details
9 Analysts
Consensus
LowTargetHigh
52.8958.1264.52
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.34-0.3-0.25
Details

Terns Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Terns Pharmaceuticals is not an exception. The market had few large corrections towards the Terns Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Terns Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Terns Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
1.74
β
Beta against Dow Jones-0.5
σ
Overall volatility
8.16
Ir
Information ratio 0.24

Terns Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Terns Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Terns Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Terns Pharmaceuticals is way too risky over 90 days horizon
Terns Pharmaceuticals appears to be risky and price may revert if volatility continues
Terns Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (88.85 M) with profit before overhead, payroll, taxes, and interest of 1000 K.
Terns Pharmaceuticals currently holds about 139.81 M in cash with (70.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.51.
Terns Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 86.0% of the company shares are owned by institutional investors
Latest headline from thelincolnianonline.com: Tern Trading Up 15.6 percent Time to Buy

Terns Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Terns Stock often depends not only on the future outlook of the current and potential Terns Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Terns Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding79.5 M
Cash And Short Term Investments358.2 M

Terns Pharmaceuticals Fundamentals Growth

Terns Stock prices reflect investors' perceptions of the future prospects and financial health of Terns Pharmaceuticals, and Terns Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Terns Stock performance.

About Terns Pharmaceuticals Performance

By examining Terns Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Terns Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Terns Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.22)(0.23)
Return On Capital Employed(0.26)(0.28)
Return On Assets(0.22)(0.23)
Return On Equity(0.23)(0.24)

Things to note about Terns Pharmaceuticals performance evaluation

Checking the ongoing alerts about Terns Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Terns Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Terns Pharmaceuticals is way too risky over 90 days horizon
Terns Pharmaceuticals appears to be risky and price may revert if volatility continues
Terns Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (88.85 M) with profit before overhead, payroll, taxes, and interest of 1000 K.
Terns Pharmaceuticals currently holds about 139.81 M in cash with (70.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.51.
Terns Pharmaceuticals has a frail financial position based on the latest SEC disclosures
Over 86.0% of the company shares are owned by institutional investors
Latest headline from thelincolnianonline.com: Tern Trading Up 15.6 percent Time to Buy
Evaluating Terns Pharmaceuticals' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Terns Pharmaceuticals' stock performance include:
  • Analyzing Terns Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Terns Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
  • Examining Terns Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Terns Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Terns Pharmaceuticals' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Terns Pharmaceuticals' stock. These opinions can provide insight into Terns Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Terns Pharmaceuticals' stock performance is not an exact science, and many factors can impact Terns Pharmaceuticals' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Terns Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Terns Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Terns Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Terns Pharmaceuticals Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation.
To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Will Pharmaceuticals sector continue expanding? Could Terns diversify its offerings? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Terns Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.02)
Revenue Per Share
0.035
Return On Assets
(0.20)
Return On Equity
(0.29)
Understanding Terns Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Terns's accounting equity. The concept of intrinsic value - what Terns Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Terns Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Terns Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.